Genesis Wealth Advisors LLC Makes New $2.03 Million Investment in iShares Biotechnology ETF (NASDAQ:IBB)

Genesis Wealth Advisors LLC bought a new position in iShares Biotechnology ETF (NASDAQ:IBBFree Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 15,383 shares of the financial services provider’s stock, valued at approximately $2,034,000. iShares Biotechnology ETF makes up about 1.8% of Genesis Wealth Advisors LLC’s holdings, making the stock its 20th biggest position.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Y Intercept Hong Kong Ltd purchased a new stake in iShares Biotechnology ETF in the fourth quarter worth approximately $511,000. Union Bancaire Privee UBP SA purchased a new stake in shares of iShares Biotechnology ETF during the fourth quarter valued at approximately $693,000. Transcend Capital Advisors LLC boosted its stake in shares of iShares Biotechnology ETF by 0.8% during the fourth quarter. Transcend Capital Advisors LLC now owns 10,958 shares of the financial services provider’s stock valued at $1,449,000 after purchasing an additional 92 shares during the period. Centricity Wealth Management LLC purchased a new stake in shares of iShares Biotechnology ETF during the fourth quarter valued at approximately $55,000. Finally, Concurrent Investment Advisors LLC boosted its stake in shares of iShares Biotechnology ETF by 11.7% during the fourth quarter. Concurrent Investment Advisors LLC now owns 4,148 shares of the financial services provider’s stock valued at $548,000 after purchasing an additional 436 shares during the period. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Price Performance

NASDAQ:IBB opened at $138.91 on Monday. iShares Biotechnology ETF has a fifty-two week low of $123.60 and a fifty-two week high of $150.57. The business has a 50 day moving average price of $135.61 and a 200-day moving average price of $140.79.

iShares Biotechnology ETF Cuts Dividend

The business also recently disclosed a dividend, which was paid on Friday, December 20th. Stockholders of record on Tuesday, December 17th were paid a dividend of $0.0624 per share. The ex-dividend date was Tuesday, December 17th.

iShares Biotechnology ETF Profile

(Free Report)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Read More

Institutional Ownership by Quarter for iShares Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.